Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Cefuroxime

Cefuroxime
In stock
250mg · 500mg
from A$112.80
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$135.37A$112.80
A$9.40 per tablet

In brief

  • In our pharmacy, you can buy cefuroxime without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging — note that cefuroxime is officially prescription‑only in most countries, so check local regulations.
  • Cefuroxime is used to treat respiratory tract infections (tonsillitis, sinusitis, pneumonia), otitis media, skin and soft‑tissue infections, early Lyme disease, uncomplicated gonorrhoea and severe systemic infections; it is a second‑generation cephalosporin that works by inhibiting bacterial cell‑wall synthesis (binding penicillin‑binding proteins) and producing bactericidal activity.
  • Usual dosages: adults commonly 250 mg PO twice daily for tonsillitis/sinusitis, 250–500 mg PO BID for otitis or skin infections, 500 mg PO BID for early Lyme disease (14–21 days), 1.5 g IM single dose for uncomplicated gonorrhoea, and IV 750 mg–1.5 g every 8 hours for severe infections; paediatric dosing typically 10–15 mg/kg twice daily (with renal adjustment as needed).
  • Forms and administration: oral film‑coated tablets (125, 250, 500 mg), oral suspension (125/5 ml, 250/5 ml) after reconstitution, powder for injection (750 mg, 1.5 g) for IV/IM use, and small‑volume intracameral eye injection preparations.
  • Onset time: bactericidal activity begins once therapeutic blood levels are reached—typically within 1–2 hours after IV administration and around 2–3 hours after oral dosing; clinical symptom improvement is often noticed within 48–72 hours.
  • Duration of action: serum half‑life is roughly 1–2 hours, with clinical dosing providing effective coverage for about 12 hours per dose; total treatment duration varies by indication (commonly 5–10 days for uncomplicated infections, 14–21 days for Lyme disease, longer for severe infections).
  • Alcohol warning: avoid alcohol while taking cefuroxime — interaction risk is low but alcohol can worsen side effects and delay recovery, so it is best avoided.
  • The most common side effect is diarrhoea.
  • Would you like to try cefuroxime without a prescription?

Critical Warnings & Restrictions

Basic Cefuroxime Information

  • INN (International Nonproprietary Name): Cefuroxime (Latin: Cefuroximum).
  • Brand Names Available In Australia: Brands listed in global registries include Zinnat, Zinacef, Ceftin, Elobact, Cefurax, Sharox, Cefuril, Oraxim and several region‑specific generics; check the TGA ARTG and local pharmacy listings for marketed brands and pack sizes.
  • ATC Code: J01DC02 (Second‑generation cephalosporin); S01AA27 (ophthalmic anti‑infective use for eye injection).
  • Forms & Dosages: Film‑coated tablets 125mg, 250mg, 500mg; oral suspension 125mg/5ml and 250mg/5ml (reconstituted); powder for injection vials 750mg and 1.5g; intracameral eye injection 1mg in 0.1ml.
  • Manufacturers In Australia: Not specified; global manufacturers include GlaxoSmithKline (Zinnat, Zinacef), Apotex and a range of generic suppliers.
  • Registration Status In Australia: Not specified in the supplied registry extract; verify TGA ARTG for current listings and approved formulations.
  • OTC / Rx Classification: Prescription‑only (Rx) in nearly all markets; not available OTC.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who is at higher risk when taking cefuroxime?

People with a known allergy to cefuroxime or other cephalosporins must not take cefuroxime.

Anyone with a history of immediate‑type beta‑lactam hypersensitivity (for example, anaphylaxis to penicillins or cephalosporins) should not receive cefuroxime.

Pregnancy and lactation are situations that require careful risk–benefit discussion with your GP or obstetrician.

Cefuroxime is generally considered safe in pregnancy but should only be used when clearly indicated and after consulting a prescriber.

In elderly patients be alert for reduced renal function which may require dose reduction based on eGFR or CrCl.

People with severe kidney impairment need dose adjustment and closer monitoring, and some guidance recommends halving doses when CrCl is under 30 mL/min.

Patients with a history of Clostridioides difficile infection or antibiotic‑associated colitis should use cefuroxime only if necessary and monitor stool frequency and symptoms closely.

Document all antibiotic allergies in My Health Record and prescriber notes, and ensure the pharmacist records the allergy on dispensing records.

Emergency signs that require immediate medical attention include difficulty breathing, swelling of the face or throat, severe rash, high fever, persistent or bloody diarrhoea and new‑onset seizures.

  • Checklist — Emergency Signs: Anaphylaxis (wheezing, throat tightness), severe generalized rash, high fever with rigors, profuse watery or bloody diarrhoea, sudden jaundice or severe abdominal pain.
Renal Trigger Usual Action
eGFR/CrCl ≥50 mL/min No routine adjustment; monitor if elderly.
CrCl 30–49 mL/min Consider dose reduction and extend dosing interval as per prescriber advice.
CrCl <30 mL/min Use reduced dose (often half dose) and consult renal dosing guidance.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Does cefuroxime affect your ability to drive?

Cefuroxime is not commonly associated with profound sedation, but some people report CNS side effects such as dizziness, headache or confusion.

If you develop dizziness, drowsiness, visual disturbance or confusion while taking cefuroxime you should not drive, operate heavy machinery or perform safety‑critical tasks.

Under Australian workplace health and safety laws, employees must report any medication effects that could impair performance and employers must manage safety risks.

If you work in safety‑sensitive roles, discuss potential side effects with your prescriber or pharmacist before starting cefuroxime.

Q&A — Can I Drive After Taking It In Australia?

Short answer: Usually yes, if you feel normal and have no symptoms affecting concentration or vision.

Most people taking cefuroxime experience only mild side effects such as minor headache, nausea or short‑lived dizziness, which do not prevent driving.

If you notice dizziness, drowsiness, blurred vision, confusion or any change that reduces your alertness, do not drive or operate machinery until the symptom has resolved and you feel back to normal.

If a reaction is severe or sudden — for example, difficulty breathing, swelling of the face or throat, or collapse — call Triple Zero (000) immediately and seek emergency care.

Report any concerning adverse reactions to your GP and pharmacist and consider lodging a report with the Therapeutic Goods Administration using their adverse event reporting system.

If you work in safety‑critical roles inform your employer and discuss medical clearance before returning to full duties.

Usage Basics

INN, Brand Names Available (Australian Context)

The International Nonproprietary Name (INN) is cefuroxime, sometimes listed in formularies as cefuroxime axetil for the oral form and cefuroxime sodium for parenteral forms.

Common international brands recorded in registries include Zinnat (tablets and oral suspension), Zinacef (injection vials), Ceftin (tablets) and various generics such as Elobact and Cefurax.

In Australia both branded and generic cefuroxime formulations may appear depending on supplier and ARTG listings, so check local pharmacy stock and the TGA ARTG for exact marketed names and pack sizes.

  • INN: cefuroxime.
  • Common international brands: Zinnat, Zinacef, Ceftin, Elobact, Cefurax.
  • Form distinction: oral form is usually cefuroxime axetil; IV/IM forms are cefuroxime sodium.

Legal Classification (TGA‑Approved, PBS Considerations)

Cefuroxime is classified as a prescription‑only medicine in nearly all markets and must be supplied on a valid prescription in Australia.

Specific cefuroxime brands and formulations must be listed on the TGA ARTG to be legally supplied in Australia, so pharmacists and prescribers should check the ARTG number for the product they intend to supply.

PBS subsidy and listing depend on formulation and approved indications and can change over time, so always confirm current PBS schedule details before advising a patient about cost.

Patients should be encouraged to ask their pharmacist about PBS entitlements, concession pricing and whether a brand‑generic substitution is appropriate for cost savings.

Checklist before supply: verify prescription validity, confirm ARTG listing for the brand supplied, check PBS item numbers if subsidy is requested and record allergy status and relevant clinical indication on the dispensing record.

Dosing Guide (Practical Regimens And Adjustments)

Standard Regimens (PBS Reference Dosing)

What dose will my prescriber usually give?

Typical adult oral regimens are: 250 mg orally twice daily for tonsillitis, pharyngitis and sinusitis for 5–10 days.

For otitis media and community lower respiratory infections dosing is commonly 250–500 mg orally twice daily for 7–10 days depending on severity.

Early Lyme disease is often treated with 500 mg orally twice daily for 14–21 days where indicated.

Uncomplicated gonorrhoea has been treated with a 1.5 g intramuscular single dose in some registries, though local guidance and resistance patterns should guide therapy.

Severe systemic infections may require parenteral dosing such as IV 750 mg–1.5 g every 8 hours under hospital care.

Paediatric dosing is weight‑based: commonly 10–15 mg/kg twice daily for many indications, with specific ranges of 10 mg/kg to 15 mg/kg depending on the condition.

Indication Typical Adult Dose Typical Duration
Tonsillitis/Pharyngitis/Sinusitis 250 mg PO twice daily 5–10 days
Otitis Media / Lower RTI 250–500 mg PO twice daily 7–10 days
Skin / Soft Tissue Infection 250–500 mg PO twice daily 7–10 days
Early Lyme Disease 500 mg PO twice daily 14–21 days
Uncomplicated Gonorrhoea 1.5 g IM single dose Single dose
Severe/Meningitis (IV) 750 mg–1.5 g IV q8h Individualised

Adjustments For Comorbidities

Renal impairment requires dose adjustment and monitoring; use eGFR/CrCl calculators when prescribing for elderly or renal‑impaired patients.

For severe renal impairment (CrCl <30 mL/min) a reduced dose is commonly recommended and prescribers should consult renal dosing charts.

Elderly patients do not require an automatic dose reduction for age alone but do require assessment of renal function as above.

Severe hepatic impairment generally does not require dose adjustment unless other clinical concerns exist.

For pregnancy and lactation discuss risks and benefits with the prescriber and consider alternate therapy only if clearly indicated.

Q&A — What If I Miss A Dose?

If you miss a single dose of cefuroxime take it as soon as you remember.

If it is almost time for the next scheduled dose skip the missed dose and continue with the usual dosing times.

Do not double up or take two doses at once to make up for a missed dose as this increases risk of side effects.

If you have missed several doses or are unsure how many were missed seek advice from your prescriber or pharmacist about restarting or adjusting therapy.

If symptoms worsen or do not improve after a reasonable period, contact the prescriber for review rather than extending or repeating courses without guidance.

In the event of a suspected overdose, watch for severe CNS effects including seizures, marked confusion or coma and seek emergency care immediately.

Supportive management is the mainstay for overdose; if recently ingested activated charcoal may be considered and haemodialysis can assist elimination in severe renal impairment.

Interaction Chart (Food, Drink And Medicines)

Food And Drinks (Australian Diet Context)

Absorption of oral cefuroxime axetil can be reduced by concurrent use of antacids and some H2‑blockers, so separate dosing where possible.

Probenecid increases serum cefuroxime levels and can prolong its action by reducing renal tubular secretion.

Cefuroxime is not commonly linked with a disulfiram‑like reaction, but patients are advised to avoid alcohol while they are taking any antibiotic until they know how they tolerate it.

Separating doses from antacids by two hours is a practical counselling point to preserve oral absorption.

  • Avoid simultaneous antacid use; space by ~2 hours.
  • Be cautious with alcohol until tolerance is known and to minimise GI upset.
  • Notify your prescriber if you take probenecid or gout medications.

Common Drug Conflicts

Some medicines interact with cefuroxime or require monitoring when combined.

Probenecid increases cefuroxime serum concentrations and can prolong therapeutic levels.

Coadministration with warfarin or other oral anticoagulants may increase INR in some patients; monitor clotting if antibiotics are started.

Concurrent use of other nephrotoxic drugs warrants renal monitoring because combined effects may increase the risk of renal adverse events.

Live vaccines may have reduced effectiveness if given during a course of antibiotics in some clinical scenarios; discuss timing with immunisation services.

Drug Effect Counselling Point
Probenecid Increases cefuroxime levels Inform prescriber; may prolong action.
Antacids / H2 blockers Reduce oral absorption Space doses by ~2 hours.
Warfarin / anticoagulants Possible increased INR Monitor INR during antibiotic therapy.
Other nephrotoxics Increased renal risk Monitor renal function.

User Reports & Trends (Australian Patient Feedback)

What do Australians say about taking cefuroxime?

Patient reviews and pharmacy feedback commonly mention gastrointestinal upset such as diarrhoea and nausea as the most frequent complaints.

Rash and allergy concerns are commonly reported by users who have a prior penicillin allergy and seek alternatives.

Many patients report effective symptom resolution for ear, throat and skin infections when cefuroxime is prescribed for susceptible organisms.

Price sensitivity is a recurring theme, with patients asking about generic options and PBS subsidy to reduce out‑of‑pocket cost.

There has been an increase in telehealth prescribing and e‑prescriptions since COVID, and patients report convenience as well as occasional issues with same‑day availability at local pharmacies.

  • Top reported patient issues: gastrointestinal upset, rash/allergy concerns, cost/availability, therapy effectiveness, questions about penicillin cross‑reactivity.
Aspect Typical Sentiment
Effectiveness Generally positive for appropriate infections
Side Effects Commonly GI upset; occasional rash
Access Variable; price sensitive

If patients suspect an adverse event they should verify details with their GP or pharmacist and report the event to the TGA to help monitor safety at a population level.

Remember that online reviews and forum comments are anecdotal and should not replace clinical guidance found in Therapeutic Guidelines or from a treating clinician.

Access & Purchase Options (Australian Retail And Telehealth)

National Chains And Community Pharmacies

Major pharmacy chains including Chemist Warehouse, Priceline and TerryWhite Chemmart, as well as independent community pharmacies, supply prescription antibiotics subject to ARTG listings and wholesaler stock.

Patients should compare price and ask pharmacists about generic options and PBS eligibility to reduce costs.

  • What to bring to the pharmacy: the original prescription or e‑script, concession card if eligible, a list of current medicines, and details of any allergies.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are permitted in Australia and can be sent to a nominated pharmacy for dispensing or to an online pharmacy for postage.

Online pharmacies require a valid prescription and will post medication, keeping in mind shipping times and handling for special products.

Injection vials must be handled correctly and are typically supplied for administration in clinic or hospital settings rather than by postal delivery.

Rural and remote patients may experience longer delivery times and should discuss earlier prescribing to avoid stock‑outs.

In our online pharmacy, cefuroxime is available without a prescription, with discreet delivery to Australia in 9-21 days.

Access Route Typical Pros Typical Cons
Walk‑in Community Pharmacy Immediate counselling, same‑day supply if stock on hand Price varies, may need substitution
Online Pharmacy Convenience, home delivery Requires valid script; delivery time
Rural Supply Local continuity of care Longer delivery and limited stock

Mechanism & Pharmacology (Plain And Clinical)

Simplified Explanation

Cefuroxime is a second‑generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis.

It binds to penicillin‑binding proteins causing cell wall disruption and bacterial lysis in susceptible organisms.

Its spectrum covers a range of Gram‑positive and some Gram‑negative bacteria and shows relative resistance to certain beta‑lactamases compared with older penicillins.

Clinical Terms And Formulations

The oral formulation is commonly administered as cefuroxime axetil, an oral prodrug with improved bioavailability compared with cefuroxime itself.

Parenteral formulations are presented as cefuroxime sodium for IV or IM administration and for intracameral ophthalmic prophylaxis in some surgical settings.

Pharmacokinetics: absorption, onset and half‑life vary with route and renal function, and probenecid can reduce renal excretion and prolong serum concentrations.

  • Definitions: Cefuroxime axetil = oral prodrug; Cefuroxime sodium = IV/IM powder for reconstitution.
  • ATC Classification: J01DC02.

Indications & Off‑Label Uses (What Clinicians Prescribe)

TGA/Approved Indications (Practical List)

Common indications used internationally and in practice include tonsillitis, pharyngitis, sinusitis, otitis media, community‑acquired lower respiratory infections and skin and soft tissue infections.

Typical dosing examples include 250 mg PO twice daily for upper respiratory infections and 250–500 mg PO twice daily for otitis and skin infections.

Oral cefuroxime axetil is often used as step‑down therapy after intravenous cefuroxime where the organism is susceptible.

Intracameral ophthalmic cefuroxime is used in some surgical prophylaxis protocols in certain markets for reducing postoperative infection risk.

Off‑Label Uses In Australian Practice

Off‑label applications include step‑down oral therapy from IV cefuroxime during hospital to community transition when culture and susceptibility data support the change.

Selective outpatient management of complicated urinary tract infections or other infections may use oral cefuroxime when sensitivities and clinical context permit, documented with rationale.

Indication Typical Dose PBS Note
Tonsillitis 250 mg PO BD × 5–10 days Check PBS listing for subsidy
Otitis Media 250–500 mg PO BD × 7–10 days Check PBS listing for subsidy
Step‑down From IV Therapy As per culture sensitivity Usually not PBS‑specific; document rationale

Checklist for off‑label use: confirm culture and sensitivity, document clinical rationale, obtain informed consent and arrange follow‑up.

Key Clinical Findings (Evidence Summary 2022–2026)

What does the recent evidence say about cefuroxime?

Systematic reviews and randomised trials through recent years continue to show cefuroxime as an effective option for many common community infections, with a safety profile consistent with other beta‑lactams.

Evidence supports the use of oral cefuroxime axetil as an effective oral step‑down after IV therapy when the pathogen is susceptible and clinical improvement is evident.

For surgical prophylaxis, including intracameral ophthalmic use where protocolised, cefuroxime has been associated with reduced postoperative infection in some settings.

Clinicians should consult up‑to‑date guidance such as Therapeutic Guidelines (Australia), RACGP recommendations and local antibiograms when selecting therapy to reflect resistance patterns.

  • Key sources to consult: Therapeutic Guidelines (Australia), RACGP antibiogram/guidance, TGA ARTG entries, PubMed and clinicaltrials.gov for recent trials.

Checklist for evaluating new evidence: check study population and setting, compare outcomes to local resistance patterns, and consider applicability to the individual patient.

Alternatives Matrix (Clinical And PBS Perspective)

PBS‑Listed Alternatives Comparison Table

Agent Class Common Indications Pros Cons
Amoxicillin‑clavulanate Beta‑lactam with inhibitor Respiratory, skin infections Broader beta‑lactamase coverage More GI side effects; cost may vary with PBS
Cefixime Third‑generation cephalosporin Oral therapy including gonorrhoea where indicated Once‑daily options; good Gram‑negative coverage Less activity against streptococci; PBS status variable
Cefaclor Second‑generation cephalosporin Upper respiratory infections Similar spectrum Less used; availability and PBS listing variable

Pros And Cons Checklist

  • Consider pathogen susceptibility and local antibiogram results.
  • Assess allergy history and potential penicillin cross‑reactivity.
  • Review renal and hepatic function for dosing needs.
  • Compare side‑effect profiles and patient tolerance.
  • Factor PBS cost, subsidy status and patient adherence (once vs twice daily).

Common Questions (Pharmacy Consultation FAQs)

Is cefuroxime safe in pregnancy?

Cefuroxime is generally considered safe in pregnancy but should only be used when clearly indicated and after discussion with the prescriber.

Will cefuroxime treat a viral cold?

No; antibiotics, including cefuroxime, do not treat viral infections such as common colds or most sore throats of viral origin.

Can someone with a penicillin allergy take cefuroxime?

Assess the nature and severity of the penicillin reaction; a history of immediate anaphylaxis to penicillins is a relative contraindication due to potential cross‑reactivity and requires specialist or prescriber review.

What side effects should patients expect?

Common side effects include gastrointestinal upset (diarrhoea, nausea), skin rash and headache; rare effects include a positive Coombs test and CNS effects such as dizziness or seizures in overdose.

  • Pharmacist checklist: verify allergy, check renal function, advise about missed doses, and explain how to report adverse events to the TGA.

Price & Access Comparison (Pharmacy, Online, Rural)

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Source Typical Price Range PBS Subsidy Prescription Required
Local Community Pharmacy Varies by brand; ask pharmacist Possible for some formulations/indications Yes
Discount Chain (e.g. Chemist Warehouse) Often competitive; check for generics Depends on PBS listing Yes
Online Pharmacy Varies; factor shipping Depends on PBS rules and script Yes, valid e‑script required
Hospital Supply (IV forms) Not retail priced Provided under hospital funding Prescribed/administered in hospital

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Plan ahead for rural supply; discuss stock‑outs early with prescriber.
  • Ask the pharmacist about generic substitutes and PBS entitlements to reduce cost.
  • For injectable forms, arrange administration in clinic or hospital; do not attempt to self‑administer unless trained and authorised.
  • Confirm any cold‑chain requirements for vials and reconstituted suspensions with the dispensing pharmacy.

Registration & Regulation (TGA, PBS Practicalities)

TGA Approval

Products intended for supply in Australia must be listed on the TGA ARTG and show the ARTG number on documentation where required.

Pharmacists should verify ARTG entries for the specific brand and formulation before supply or when advising patients about availability.

PBS Subsidy Details

PBS listings for cefuroxime vary by formulation and indication and may require authority prescriptions for subsidy in particular circumstances.

Prescribers should code the relevant PBS item number where applicable and counsel patients about likely out‑of‑pocket costs if a PBS concession does not apply.

  • Checklist for prescribers and pharmacists: verify ARTG and PBS item numbers, confirm authority requirements, and document supply in patient records.

Storage & Handling (Home And Pharmacy)

Household Storage In Australian Climate (Heat/Humidity)

Store tablets at room temperature, ideally between 15–25°C, in a dry place away from direct sunlight.

In hot or humid Australian conditions keep medicines in air‑conditioned rooms or a cool cabinet rather than bathrooms or kitchens.

Keep all medicines out of reach and sight of children.

Cold‑Chain And Pharmacy Handling

Reconstituted oral suspensions should be refrigerated and discarded after 10 days as per product instructions.

Injection vials are typically stored below 25°C and protected from light; reconstituted parenteral solutions should be used promptly according to the manufacturer’s directions.

Product Storage Requirement
Tablets Room temperature 15–25°C, dry
Reconstituted Suspension Refrigerate; discard after 10 days
Injection Vials Store below 25°C; protect from light
  • Handling steps: follow manufacturer reconstitution instructions, label with date/time of reconstitution, and dispose of unused suspension safely after expiry.

Guidelines For Proper Use (Pharmacist Counselling & Patient Steps)

Australian Pharmacist Counselling Style

Start by confirming the indication and intended duration of therapy with the patient.

Check and record allergies, especially to penicillins or cephalosporins, and confirm renal function where relevant.

Explain the dosing schedule and the importance of completing the prescribed course unless advised otherwise by the prescriber.

Warn about common side effects such as diarrhoea, nausea and rash and advise patients to seek urgent care for anaphylaxis, severe diarrhoea or jaundice.

Advise on spacing from antacids, and discuss interactions with probenecid and the need for INR monitoring if the patient is on warfarin.

Patient Advice From PBS And National Health Authorities

Encourage patients to report adverse events to the TGA and to their prescriber and pharmacist.

Direct patients to reliable resources such as Therapeutic Guidelines, NPS MedicineWise and their GP for condition‑specific guidance.

  • Patient home checklist: complete the full course, store medicine correctly, report new or severe side effects, and follow up if symptoms worsen after 48–72 hours.

Return to care if there is persistent fever, worsening respiratory symptoms, severe or bloody diarrhoea, or any signs of allergic reaction.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Hobart Tasmania 9–14 days
Canberra Australian Capital Territory 9–14 days
Darwin Northern Territory 14–21 days
Gold Coast Queensland 9–14 days
Newcastle New South Wales 9–14 days
Wollongong New South Wales 9–14 days
Geelong Victoria 9–14 days
Townsville Queensland 14–21 days
Albury New South Wales / Victoria 14–21 days
Broome Western Australia 14–21 days

Related products